Drug-coated balloon

Original Contribution

Retrospective Review of Directional Atherectomy and Drug-Coated Balloon Use in a PAD Safety-Net Population

04/01/2023

Shea E. Hogan , MD;

Matthew Holland , MD, FACC, FSCAI;

Joseph Burke , MD;

Paisley Johnson , MD;

Demetria McNeal , MD;

Lisa Cicutto , MD;

Mark Nehler , MD;

Pamela N. Peterson , MD, MSPH;

The authors retrospectively reviewed outcomes of patients with peripheral artery disease who underwent directional atherectomy and drug-coated balloon during lower extremity revascularization.

The authors retrospectively...

04/01/2023

Journal of Invasive Cardiology

Murasato Quadrifurcation Lesion Figure 1

Clinical Images

Stentless Treatment for a Left Main Quadrifurcation Lesion

12/01/2022

Yoshinobu Murasato , MD, PhD;

Soichiro Omura , MD;

Shoko Fukuda , MD;

A 69-year-old man underwent coronary intervention for stenosis in the left main (LM) quadrifurcation lesion with SYNTAX score 23 (SYNTAX II score: coronary intervention 27.5, bypass surgery 33.5) 1 week after primary stenting in the right...

A 69-year-old man underwent...

12/01/2022

Journal of Invasive Cardiology

Original Research

Clinical Performance of a Paclitaxel Drug-Coated Balloon in Real-World Percutaneous Coronary Intervention Practice: The PEARL Registry

06/01/2022

Selina Vlieger , MSc;

Jin M. Cheng , MD, PhD;

Rohit M. Oemrawsingh , MD, PhD;

Auke P.J.D. Weevers , MD;

Jawed Polad , MD;

Ben Gho , MD, PhD;

Martijn Meuwissen , MD, PhD;

Eric Boersma , PhD;

Peter den Heijer , MD, PhD;

Alexander JJ. IJsselmuiden , MD, PhD;

Randomized controlled trials for in-stent restenosis (ISR) and de novo lesions in small-diameter vessels have shown promising results, but data on DCB use in real-world practice are still scarce. The aim of the PEARL (Paclitaxel-Eluting...

Randomized controlled trials for...

06/01/2022

Journal of Invasive Cardiology

Giannopoulos Drug-Eluting Stent Figure 1

Original Contribution

Concomitant Drug-Coated Balloon Angioplasty With Bail-Out Use of Eluvia Drug-Eluting Stent: Is There Any Downside to a Double Dose of Paclitaxel?

06/01/2022

Eric A. Secemsky , MD, MSc, RPVI, FACC, FAHA, FSCAI;

Ehrin J. Armstrong , MD, MSc, FACC;

Stefanos Giannopoulos , MD;

The application of 2 distinct and simultaneously applied drug-delivery platforms for the treatment of peripheral artery disease has not been studied. This study investigated the outcomes of femoropopliteal disease treated with drug-coated...

The application of 2 distinct...

06/01/2022

Journal of Invasive Cardiology

Original Contribution

Two-Year Clinical Outcomes of the REVELATION Study: Sustained Safety and Feasibility of Paclitaxel-Coated Balloon Angioplasty Versus Drug-Eluting Stent in Acute Myocardial Infarction

01/03/2022

Sanchez Manning ;

Rodolfo Raul Sanchez Rosado ;

Maricruz Aceves Valdez ;

Nicola S. Vos , MD;

Mark S. Patterson , MBBS, PhD, MD, MRCP;

Alejandro Vela Torres ;

Giovanni Amoroso , MD, PhD;

Gerardo Joel Maya Vacio ;

The randomized REVELATION trial showed that in the setting of STEMI, a drug-coated balloon strategy was non-inferior to a drug-eluting stent strategy in terms of fractional flow reserve assessed at 9 months. The aim of the present study is to...

The randomized REVELATION trial...

01/03/2022

Journal of Invasive Cardiology

Original Contribution

Rationale and Design of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Total Occlusions

06/08/2021

Antonio Micari , MD, PhD;

Francesco Liistro , MD;

Jeffrey J. Popma , MD, FACC, FSCAI;

This is a pilot feasibility study and the objective is to evaluate the safety and effectiveness of the investigational device, IN.PACT 014 drug-coated balloon, compared with standard PTA in patients with CLI with CTOs of BTK arteries.

This is a pilot feasibility...

06/08/2021

Cath Lab Digest

Paclitaxel Drug-Coated Balloon After Bare-Metal Stent Implantation, an Alternative Treatment to Drug-Eluting Stent in High Bleeding Risk Patients (The Panelux Trial)

03/28/2019

Jared Betz , MD;

Joseph M. Keenan , MD;

Joseph Kohut ;

Damian Grovas Abad , MD;

Joseph V. Lombardi , MD, FACS;

Joseph Luiz ;

Joseph M. Anain Jr., DPM;

Mike Daniels , DPM;

Benjamin Faurie , MD, PhD;

Joseph M. Connors , MD;

Florence Leclercq , MD, PhD;

Guillaume Cayla , MD, PhD;

Prolonged dual-antiplatelet therapy in high bleeding risk (HBR) patients undergoing percutaneous coronary intervention can be challenging. We assessed the clinical safety of bare-metal stent implantation followed by drug-coated balloon...

Prolonged dual-antiplatelet...

03/28/2019

Journal of Invasive Cardiology